Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy

Int J Clin Pharmacol Res. 2003;23(4):129-34.

Abstract

Diabetic vascular complication is a leading cause of acquired blindness, end-stage renal failure, a variety of neuropathies and accelerated atherosclerosis, which could account for disabilities and high mortality rates in patients with diabetes. Chronic hyperglycemia is essentially involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic derangements. In this review, we discuss the molecular mechanisms of diabetic retinopathy and nephropathy, especially focusing on advanced glycation end products (AGEs) and their receptor (RAGE) system. Several types of AGE inhibitors and their therapeutic implications in diseases, including diabetic microangiopathy, will be discussed in the next review article.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Diabetic Angiopathies / etiology*
  • Diabetic Angiopathies / physiopathology
  • Diabetic Nephropathies / etiology*
  • Diabetic Nephropathies / physiopathology
  • Diabetic Retinopathy / etiology*
  • Diabetic Retinopathy / physiopathology
  • Glycation End Products, Advanced / adverse effects*
  • Glycation End Products, Advanced / metabolism
  • Humans

Substances

  • Glycation End Products, Advanced